MA41544A - Dosages de panobinostat pour le traitement du myélome multiple - Google Patents
Dosages de panobinostat pour le traitement du myélome multipleInfo
- Publication number
- MA41544A MA41544A MA041544A MA41544A MA41544A MA 41544 A MA41544 A MA 41544A MA 041544 A MA041544 A MA 041544A MA 41544 A MA41544 A MA 41544A MA 41544 A MA41544 A MA 41544A
- Authority
- MA
- Morocco
- Prior art keywords
- panobinostat
- dosage
- treatment
- multiple myeloma
- myeloma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562118254P | 2015-02-19 | 2015-02-19 | |
US201562119571P | 2015-02-23 | 2015-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41544A true MA41544A (fr) | 2017-12-26 |
Family
ID=55405393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041544A MA41544A (fr) | 2015-02-19 | 2016-02-16 | Dosages de panobinostat pour le traitement du myélome multiple |
Country Status (19)
Country | Link |
---|---|
US (3) | US20190388393A1 (fr) |
EP (1) | EP3258933A1 (fr) |
JP (2) | JP2018507216A (fr) |
KR (1) | KR20170118798A (fr) |
CN (1) | CN107249596A (fr) |
AU (2) | AU2016221327A1 (fr) |
BR (1) | BR112017017594A2 (fr) |
CA (1) | CA2976755A1 (fr) |
CL (1) | CL2017002116A1 (fr) |
IL (1) | IL253895A0 (fr) |
MA (1) | MA41544A (fr) |
MX (1) | MX2017010577A (fr) |
PH (1) | PH12017501494A1 (fr) |
RU (1) | RU2729425C2 (fr) |
SG (1) | SG11201706521XA (fr) |
TN (1) | TN2017000356A1 (fr) |
TW (1) | TW201630602A (fr) |
WO (1) | WO2016132303A1 (fr) |
ZA (1) | ZA201705363B (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110314222B (zh) * | 2019-08-07 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324025A (zh) * | 2005-08-03 | 2015-02-04 | 诺华股份有限公司 | Hdac抑制剂在治疗骨髓瘤中的用途 |
MX2008015901A (es) | 2006-06-12 | 2009-01-12 | Novartis Ag | Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]met il]fenil]-2e-2-propenamida. |
MX2009008584A (es) * | 2007-02-15 | 2009-08-18 | Novartis Ag | Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer. |
US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
US8263578B2 (en) * | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
US20160022683A1 (en) * | 2013-03-14 | 2016-01-28 | Pharmacyclics Llc | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
-
2016
- 2016-02-16 MA MA041544A patent/MA41544A/fr unknown
- 2016-02-17 JP JP2017544017A patent/JP2018507216A/ja active Pending
- 2016-02-17 BR BR112017017594-0A patent/BR112017017594A2/pt not_active IP Right Cessation
- 2016-02-17 RU RU2017132445A patent/RU2729425C2/ru active
- 2016-02-17 KR KR1020177025892A patent/KR20170118798A/ko unknown
- 2016-02-17 EP EP16705834.6A patent/EP3258933A1/fr active Pending
- 2016-02-17 CA CA2976755A patent/CA2976755A1/fr not_active Abandoned
- 2016-02-17 SG SG11201706521XA patent/SG11201706521XA/en unknown
- 2016-02-17 WO PCT/IB2016/050850 patent/WO2016132303A1/fr active Application Filing
- 2016-02-17 CN CN201680011020.6A patent/CN107249596A/zh active Pending
- 2016-02-17 TN TNP/2017/000356A patent/TN2017000356A1/en unknown
- 2016-02-17 MX MX2017010577A patent/MX2017010577A/es unknown
- 2016-02-17 AU AU2016221327A patent/AU2016221327A1/en not_active Abandoned
- 2016-02-17 TW TW105104654A patent/TW201630602A/zh unknown
-
2017
- 2017-08-08 ZA ZA2017/05363A patent/ZA201705363B/en unknown
- 2017-08-08 IL IL253895A patent/IL253895A0/en unknown
- 2017-08-17 PH PH12017501494A patent/PH12017501494A1/en unknown
- 2017-08-18 CL CL2017002116A patent/CL2017002116A1/es unknown
-
2019
- 2019-02-08 AU AU2019200876A patent/AU2019200876B2/en not_active Expired - Fee Related
- 2019-09-03 US US16/558,598 patent/US20190388393A1/en not_active Abandoned
- 2019-10-29 US US16/667,184 patent/US20200093795A1/en not_active Abandoned
-
2021
- 2021-04-09 JP JP2021066389A patent/JP2021105048A/ja active Pending
-
2022
- 2022-08-16 US US17/889,029 patent/US20230181529A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2017002116A1 (es) | 2018-05-18 |
WO2016132303A1 (fr) | 2016-08-25 |
JP2018507216A (ja) | 2018-03-15 |
US20230181529A1 (en) | 2023-06-15 |
MX2017010577A (es) | 2017-12-07 |
RU2017132445A (ru) | 2019-03-20 |
US20190388393A1 (en) | 2019-12-26 |
AU2019200876A1 (en) | 2019-02-28 |
PH12017501494A1 (en) | 2018-01-29 |
AU2016221327A1 (en) | 2017-08-31 |
IL253895A0 (en) | 2017-10-31 |
JP2021105048A (ja) | 2021-07-26 |
BR112017017594A2 (pt) | 2018-05-08 |
TN2017000356A1 (en) | 2019-01-16 |
SG11201706521XA (en) | 2017-09-28 |
KR20170118798A (ko) | 2017-10-25 |
EP3258933A1 (fr) | 2017-12-27 |
RU2017132445A3 (fr) | 2019-09-23 |
TW201630602A (zh) | 2016-09-01 |
US20200093795A1 (en) | 2020-03-26 |
AU2019200876B2 (en) | 2020-05-28 |
RU2729425C2 (ru) | 2020-08-06 |
CA2976755A1 (fr) | 2016-08-25 |
CN107249596A (zh) | 2017-10-13 |
ZA201705363B (en) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA45192A (fr) | Traitement d'association | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
DK3424534T3 (da) | Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator | |
DK3265421T3 (da) | Doseringssystem | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA52906A (fr) | Procédé de préparation d'amg 416 | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA41123A (fr) | Polythérapie pour le traitement du cancer |